Sydney, Australia 13 December 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has been granted Ethics Approval by the St Vincent Hospital (Melbourne) Human Research Ethics Committee for the Company’s clinical trial of SARTATE™ for meningioma. Clarity filed its ethics submission for the…
Sydney, Australia 6 December 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has successfully in-licensed a patent application on a Prostate Specific Membrane Antigen (PSMA) targeting agent for imaging and treating prostate cancer from the University of Melbourne. Clarity is also pleased to…
Clarity Pharmaceuticals was featured in ATSE Focus magazine, a publication issued by the Australian Academy of Technology and Engineering (ATSE), which publishes articles, reviews and letters to address national technology issues and key policy issues – such as innovation and productivity. The article highlights the benefits of using the Copper-64/Copper-67 pairing in the area of personalised medicine…
Sydney, Australia 8 November 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that site activation at the Children’s Hospital at Westmead in Sydney has been completed and recruitment has commenced for its SARTATE™ Kids trial. Clarity’s SARTATE™ Kids trial is a Positron Emission Tomography (PET)…
Clarity Pharmaceuticals’ partner, the Idaho Accelerator Center at Idaho State University, was awarded the Early Stage Innovation of the Year at the 2017 Idaho Innovation Awards. This achievement was for the development of a new and efficient process for producing copper-67. This process enables copper-67 to be manufactured in sufficient quantities and at a high quality…
Sydney, Australia 31 October 2017 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Professor Richard Wahl has joined their scientific advisory group. Richard Wahl, M.D., is the Elizabeth Mallinckrodt Professor, Chairman of the Department of Radiology and Director of the Mallinckrodt Institute of Radiology…
Sydney, Australia 15 August 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has been granted Ethics Approval by The Children’s Hospital at Westmead for its SARTATE™ Kids clinical trial for neuroblastoma. Clarity filed its ethics submission to the Sydney Children’s Hospital Network Human…
Sydney, Australia 4 July 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Kathleen Miller, a US based experienced business development executive, to Clarity’s team. Dr Miller has over 25 years of experience in the pharmaceutical, medical imaging, and medical device industries,…
Sydney, Australia, 29 June 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has raised AU$4 million to develop its clinical pipeline using its proprietary theranostic technology and expand its presence in Europe and the US. The investment round includes strong support from current shareholders and a small number of…
Sydney, Australia 9 June 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the presentation of their poster at the upcoming 2017 Annual Meeting of Society for Nuclear Medicine and Medical Imaging (SNMMI) in Denver. Clarity’s Head of Quality, Dr Colin Biggin (also with RNT consulting),…